After an "unacceptable" year for earnings, Michelle Keefe is tasked with getting the global contract research organization back on track amid a cloudy outlook for life sciences and the pharmaceutical industry.
After an "unacceptable" year for earnings, Michelle Keefe is tasked with getting the global contract research organization back on track amid a cloudy outlook for life sciences and the pharmaceutical industry.
